Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders

Vandana Singh
1 min read
0
In this article:

  • Wave Life Sciences Ltd (NASDAQ: WVE) and GSK plc (NYSE: GSK) have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006.

  • The discovery collaboration has an initial four-year research term.

  • The collaboration includes two main components. The first is a discovery collaboration that enables GSK to advance up to eight programs and Wave to advance up to three programs.

  • In addition to these programs, GSK receives the exclusive global license for Wave's preclinical program, WVE-006.

  • Wave will receive an upfront payment of $170 million, including $120 million in cash and a $50 million equity investment.

  • For the WVE-006 program, Wave is eligible to receive up to $225 million in development and launch milestones, up to $300 million in sales-related milestone payments, and tiered sales royalties.

  • Development and commercialization responsibilities will transfer to GSK after Wave completes the first-in-patient study.

  • For each of GSK's eight collaboration programs, Wave will be eligible to receive up to $130-$175 million in development and launch milestones and $200 million in sales-related milestones, along with tiered sales royalties.

  • Price Action: WVE shares are up 21.9% at $4.40 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories